EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Angina Severity and Symptom Improvement Are Associated With Diagnostic Acetylcholine Provocation Dose in Vasospastic Angina

C Crooijmans iD, Tijn P J Jansen iD, Joan G Meeder iD, Valeria Paradies iD, Annemiek M J de Vos iD, Pier Woudstra iD, Tessel N E Vossenberg iD, Tim P van de Hoef iD, Nicola S Vos iD, Els G M Olde Bijvank, Stijn C H van den Oord iD, Patty Winkler iD und 13 weitere

Journal of the American Heart Association · 2025

DOI: 10.1161/jaha.124.037913 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von C Crooijmans und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology Radboud University Medical Centre Nijmegen The Netherlands. Hauptthemen laut MEDLINE: Acetylcholine, Angina Pectoris, Coronary Vasospasm, Coronary Vessels. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

A coronary function test (CFT) is the recommended diagnostic test to identify coronary vasomotor dysfunction as a cause of symptoms in patients with angina and nonobstructive coronary arteries (ANOCA). Acetylcholine is the commonly used pharmacological agent for spasm provocation. We aimed to investigate an association between severity of symptoms and provocative acetylcholine dose. Methods and Results We included ANOCA patients undergoing clinically indicated CFT from the Netherlands Registry of Invasive Coronary Vasomotor Function Testing: NL‐CFT. Patients with epicardial spasm (n=251) were divided according to acetylcholine spasm triggering dose: low (2–20 mcg, EpiLOW), middle (100 mcg, EpiMIDDLE) or high (200 mcg, EpiHIGH). Patients with microvascular spasm (n=157) were analyzed irrespective of triggering dose. The patient groups were compared to each other and to a control group with negative CFT results (n=101). We assessed mean Seattle Angina Questionnaire angina frequency and summary scores at baseline and follow‐up and the proportion of patients improving or deteriorating. An inverse relationship between provocation dosage and angina frequency at baseline was found in epicardial spasm: the lower the triggering dose, the more frequently patients experienced angina (EpiLOW 48±20, EpiMIDDLE 53±21, EpiHIGH 57±19, microvascular spasm 61±21, controls 64±21, overall P =0.003). A trend was seen toward most patients improving in the high triggering dose group, and most patients deteriorating in the low triggering dose group.

Conclusions

A significant dose‐dependent relationship between spasm provocation and anginal complaints exists. Acetylcholine provocation dose could be incorporated as a risk stratification factor or surrogate outcome in future clinical trials. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06083155.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcetylcholineAngina PectorisCoronary VasospasmCoronary VesselsVasodilator AgentsAgedFemaleHumansMaleMiddle AgedDose-Response Relationship, DrugNetherlandsPredictive Value of TestsRegistriesSeverity of Illness Index

Stichwörter der Autor:innen

acetylcholineanginacoronary function testcoronary vasomotor dysfunctionspasm

Substanzen

AcetylcholineVasodilator Agents

Autor:innen und Institutionen

  • Department of Cardiology Radboud University Medical Centre Nijmegen The Netherlands.
  • Department of Cardiology VieCuri Medical Centre North-Limburg The Netherlands.
  • Department of Cardiology Maasstad Hospital Rotterdam The Netherlands.
  • Department of Cardiology Catharina Hospital Eindhoven The Netherlands.
  • Department of Cardiology Medical Centre Leeuwarden Leeuwarden The Netherlands.
  • Department of Cardiology University Medical Centre Utrecht Utrecht The Netherlands.

ORCID-Profile: C Crooijmans, Tijn P J Jansen, Joan G Meeder, Valeria Paradies, Annemiek M J de Vos, Pier Woudstra, Tessel N E Vossenberg, Tim P van de Hoef, Nicola S Vos, Stijn C H van den Oord, Patty Winkler, Martijn Meuwissen, Jos W M G Widdershoven, E Karin Arkenbout, Martin G Stoel, Yolande Appelman, Marcel A M Beijk, Aysun Cetinyurek-Yavuz, Hester M den Ruijter, Suzette E Elias-Smale, Niels van Royen, Aukelien C Dimitriu-Leen, Peter Damman

Zitieren

APA

Crooijmans, C., Jansen, T. P. J., Meeder, J. G., Paradies, V., de Vos, A. M. J., Woudstra, P., Vossenberg, T. N. E., van de Hoef, T. P., Vos, N. S., Olde Bijvank, E. G. M., van den Oord, S. C. H., Winkler, P., Meuwissen, M., Widdershoven, J. W. M. G., Arkenbout, E. K., Stoel, M. G., Appelman, Y., Beijk, M. A. M., Cetinyurek-Yavuz, A., …, & for NL‐CFT (2025). Angina Severity and Symptom Improvement Are Associated With Diagnostic Acetylcholine Provocation Dose in Vasospastic Angina. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.037913

Vancouver

Crooijmans C, Jansen TPJ, Meeder JG, Paradies V, de Vos AMJ, Woudstra P, et al. Angina Severity and Symptom Improvement Are Associated With Diagnostic Acetylcholine Provocation Dose in Vasospastic Angina. Journal of the American Heart Association. 2025. doi:10.1161/jaha.124.037913

BibTeX
@article{Crooijmans2025,
  author = {Crooijmans, C and Jansen, Tijn P J and Meeder, Joan G and Paradies, Valeria and de Vos, Annemiek M J and Woudstra, Pier and Vossenberg, Tessel N E and van de Hoef, Tim P and Vos, Nicola S and Olde Bijvank, Els G M and van den Oord, Stijn C H and Winkler, Patty and Meuwissen, Martijn and Widdershoven, Jos W M G and Arkenbout, E Karin and Stoel, Martin G and Appelman, Yolande and Beijk, Marcel A M and Cetinyurek-Yavuz, Aysun and den Ruijter, Hester M and Elias-Smale, Suzette E and van Royen, Niels and Dimitriu-Leen, Aukelien C and Damman, Peter and for NL‐CFT, for NL‐CFT},
  title = {Angina Severity and Symptom Improvement Are Associated With Diagnostic Acetylcholine Provocation Dose in Vasospastic Angina},
  journal = {Journal of the American Heart Association},
  year = {2025},
  doi = {10.1161/jaha.124.037913}
}
Kostenlos starten →